Second Sight to Discuss Second Quarter 2016 Financial Results on July 28, 2016 Conference Call
Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to
provide some useful vision to blind patients, will release its second quarter 2016 financial results on Thursday, July 28, 2016,
after the close of the U.S. financial markets.
Dr. Robert Greenberg, Chairman, Will McGuire, President and Chief Executive Officer, and Tom Miller, Chief Financial Officer,
will host a conference call to discuss the results as follows:
| Date |
|
Thursday, July 28, 2016 |
| Time |
|
4:30 p.m. EDT |
| Toll free (U.S.) |
|
(800) 891-9945 |
| International |
|
(212) 271-4657 |
| Webcast (live and replay) |
|
www.secondsight.com under the ‘Investor Relations’ section.
|
A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284
(U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21815294. The archived webcast will be
available for 30 days via the aforementioned URL.
About the Argus II® Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by
converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses,
which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to
stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to
interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain,
Switzerland, Turkey, United Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus® II Retinal
Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in
individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis
to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters
are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.
Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, President
212-452-2793
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, Senior Vice President
949-385-6449
greg.falensik@mzgroup.us
View source version on businesswire.com: http://www.businesswire.com/news/home/20160721005945/en/